Tirzepatide

What it is

Tirzepatide activates GIP and GLP-1 receptors. It is the approved, prescribable benchmark that every investigational compound on this site gets measured against - and the reason retatrutide is interesting is precisely that it beat these numbers.

The distinction between brand names is only the indication on the label: Mounjaro is tirzepatide for type 2 diabetes, Zepbound is the identical molecule approved for weight management. Insurance treats them very differently; your body does not.

Mechanism

GLP-1 agonism slows gastric emptying and increases satiety. The GIP arm potentiates glucose-dependent insulin secretion and appears to improve tolerability - dual agonism produces less nausea per unit of weight loss than GLP-1 alone, which is why tirzepatide can be pushed to more effective exposures than semaglutide before side effects force a stop.

What the evidence shows

SURMOUNT-1 - 72 weeks, adults with obesity without diabetes - produced roughly 20.9% mean weight reduction at 15 mg, against about 3% on placebo. SURPASS trials established the diabetes indication with superior HbA1c reduction versus semaglutide in head-to-head comparison.

For context against the rest of the class at comparable durations:

Note the durations differ - retatrutide reached a larger number in less time, which is the honest way to read that table.

Practical notes

• Titration is a tolerability schedule, not a race. The most common self-inflicted problem is escalating on the label's timeline when the previous dose was still causing symptoms. Holding a dose an extra 4 weeks costs nothing.
• Protein floor and resistance training. Same as the rest of the class: lean mass is the thing you lose by default and have to actively defend.
• Gallbladder risk scales with rate of loss, not just with the drug.
• Compounded versus pharmacy. Compounded tirzepatide occupied a legal grey zone during the FDA shortage period; that shortage has since been resolved, which changed what compounding pharmacies may legally produce. Grey-market "research" tirzepatide is a different thing again, with none of the identity guarantees of either.

Where it sits versus retatrutide

Tirzepatide is the answer when you want the best-evidenced option with a real supply chain, a prescriber, and a known failure profile. Retatrutide produces larger numbers in trials but exists only as unverified grey-market material with no long-term human safety record. That is the actual trade, and it is not primarily a trade about efficacy.

Side effects and warning signs

Commonly reported

• Nausea, diarrhoea, vomiting and constipation, concentrated in the weeks after each dose increase
• Reflux and burping, from delayed gastric emptying
• Injection-site reactions
• Modest resting heart rate increase
• Lean mass loss when protein intake and resistance training are neglected

Stop and get medical help

• Persistent severe abdominal pain radiating to the back - possible pancreatitis
• Right upper quadrant pain, especially during rapid weight loss - gallbladder disease is a known class effect
• Inability to keep fluids down
• Personal or family history of medullary thyroid carcinoma or MEN2 - a boxed contraindication

Sources

1. Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022trial
2. FDA approval of Zepbound for chronic weight managementregulatory

From the community

Discussion for this compound concentrates in r/tirzepatidecompound, r/Mounjaro and r/GLP1.

No threads cached yet.

Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.